Clinical Trials Logo

Relapsed Multiple Myeloma clinical trials

View clinical trials related to Relapsed Multiple Myeloma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04649060 Terminated - Clinical trials for Relapsed Multiple Myeloma

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

LIGHTHOUSE
Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a Proteasome Inhibitor (PI) (regardless of the number of prior lines of therapy), or had received at least 3 prior lines of therapy including an IMiD and a PI. Patients received treatment with melflufen+dexamethasone+daratumumab or daratumumab until documented progressive disease, unacceptable toxicity, or patient/treating physician decision. Patients in the daratumumab treatment arm had the option to receive treatment with melflufen+dexamethasone+daratumumab after confirmed progressive disease.

NCT ID: NCT04119336 Terminated - Clinical trials for Refractory Multiple Myeloma

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Start date: February 14, 2020
Phase: Phase 2
Study type: Interventional

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.